The instruction for medical use of PANAVIR® medicine the Trade name of Panavir® the International unlicensed name Is not present the Dosage form Solution for intravenous administration of 0.04 mg/ml Structure of 5 ml of solution contain active agent – * Panavir®, 200 mkg, excipients: sodium chloride, water for injections. * the purified extract of sprouts of a plant Solanum tuberosum, the main active ingredient – the hexose glycoside consisting of glucose, rhamnose, pectine sugar, mannose, xylose, a galactose, uronic acids. The description Transparent or slightly opalescent, colourless or with a light brown shade flavourless liquid. Pharmacotherapeutic group Antiviral drugs other. The ATX J05AX code the Pharmacological Pharmacokinetics At properties intravenous administration polysaccharides are found in blood in 5 min. after introduction, are taken cells of a reticuloendothelial system of a liver and spleen. Removal begins quickly, in 20-30 min. polysaccharides are found in urine and expired air. A pharmacodynamics of Panavir® – the purified extract of sprouts of a plant Solanum tuberosum, the main active ingredient – the hexose glycoside consisting of glucose, rhamnose, pectine sugar, mannose, xylose, a galactose, uronic acids. Панавир® is antiviral and immunomodulator. The main mechanism of antiviral action is connected with ability of drug to suppress synthesis of superearly and early proteins of a virus of a herpes simplex of types 1 and 2. Increases nonspecific resistance of an organism to various infections, promotes induction of interferon – an alpha and – scale leukocytes of blood and normalization of an immunogramma in viral infections. Tests showed absence at Panavira® of mutagen, teratogenic, cancerogenic, allergenic and embriotoksichesky action. In preclinical trials on laboratory animals of negative impact on reproductive function and fetation it is not established. In therapeutic doses of Panavir® it is well transferred. Has anti-inflammatory properties on experimental models of exudative hypostasis, chronic proliferative inflammation and in the test of pseudo-allergic inflammatory reaction to concanavalin A. Analgeziruyushchy action on models of the neurogenic pain and pain caused by inflammatory process and thermal irritation is shown. Possesses febrifugal action. On model of the parkinsonichesky syndrome caused by system introduction of a neurotoxin of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neuroprotective properties are shown. Has ability to improve functions of a retina and an optic nerve. Has wound healing properties in the conditions of stomach ulcer model. Indications – a herpesviridae infection of various localization (including recurrent genital herpes, herpes Zoster and oftalmogerpes) – secondary immunodeficiency against the background of infectious diseases – a Cytomegaloviral infection, including at patients with a usual miscarriage are pregnancies – is applied at women with persistent viral infection and an interferonodefitsitny state at a stage of preparation for pregnancy – persistent Cytomegaloviral infection in an aggravation stage at pregnant women in II and III trimester as a part of complex therapy – a human papillomavirus infection (anogenitalny warts) as a part of complex therapy – tick-borne encephalitis for the purpose of decrease in viral load and removal of neurologic symptomatology (an anizorefleksiya, decrease in reflexes, morbidities of points of an exit of cranial nerves, a nystagmus) as a part of complex therapy – a herpesviridae infection at immunokomprometirovanny patients with a pseudorheumatism (for strengthening of analgetic and anti-inflammatory effect of the main therapy) as a part of complex therapy – flu, a SARS as a part of complex therapy – chronic prostatitis of a bacterial etiology as a part of complex therapy – for an epitalization of ulcer defects of a gastroduodenal zone as a part of complex therapy the Route of administration and doses of Panavir® should be entered intravenously struyno slowly. The adult the Single therapeutic dose of drug makes 200 mkg of active ingredient (contents of one ampoule) which is entered once a day. Apply to treatment of a herpesviridae infection and tick-borne encephalitis of Panavir® with an interval of 48 or 24 h twice. If necessary the course of treatment can be repeated in 1 month. In a herpesviridae infection at immunokomprometirovanny patients with a pseudorheumatism apply 5 intravenous injections with an interval of 24-48 h, in case of need to repeat a course in 2 months. To treatment of secondary immunodeficiency against the background of infectious diseases of Panavir® it is applied it is triple with an interval of 48 h, then twice with an interval of 72 h. Apply to treatment of Cytomegaloviral and papillomavirusny infections of Panavir® it is triple within the first week with an interval of 48 h and twice within the second week with an interval of 72 h. In an aggravation stage at pregnant women in II and III trimester apply to treatment of persistent Cytomegaloviral infection it is triple within the first week with an interval of 48 h and twice within the second week with an interval of 72 h. Apply 5 intravenous injections to epithelization of ulcer defects of a gastroduodenal zone every other day within 10 days. Apply 2 intravenous injections with an interval of 18-24 h to treatment of a SARS and flu. With chronic bacterial prostatitis apply 5 intravenous injections with an interval of 48 h to treatment of patients. To children from 12 years 1 time a day is appointed Panavir to children in a single dose of 100 mkg intravenously struyno slowly. Apply to treatment of a herpesviridae infection of Panavir® with an interval of 24-48 h twice. If necessary the course of treatment can be repeated in 1 month. Apply to treatment of tick-borne encephalitis of Panavir® with an interval of 24 h twice. Apply to treatment of Cytomegaloviral and papillomavirusny infections of Panavir® it is triple within the first week with an interval of 48 h and twice within the second week with an interval of 72 h. Side effects Drug is transferred well, possible complications can be connected with individual intolerance and hypersensitivity to drug components. At the same time, at emergence of any undesirable side effects it is necessary to stop administration of drug and to consult with the doctor. Seldom (≥1/10,000 and & lt, 1/1,000) – allergic reactions (rash, urticaria, an itching) It is very rare (& lt, 1/10,000) – short-term falling of arterial blood pressure – slight dizziness If you noticed any other side effects which are not specified in the instruction, report about it to the doctor. Contraindications – pregnancy the I trimester and the period of a lactation (in persistent Cytomegaloviral infection in an aggravation stage) – pregnancy and the period of a lactation (according to other indications) – children’s age up to 12 years (herpesviridae infection, tick-borne encephalitis, Cytomegaloviral and papillomavirusny infections) – children’s and teenage age up to 18 years (according to other indications) – hypersensitivity to drug components Medicinal interactions are not established Special instructions At emergence of any undesirable side effects it is necessary to stop administration of drug and to consult with the doctor. At solution turbidity, drug is considered unsuitable to use. It is applied at women with persistent viral infection and an interferonodefitsitny state at a stage of preparation for pregnancy. When using at a stage of preparation for pregnancy promotes decrease in frequency of reproductive losses in Cytomegaloviral and herpesviridae infections. Use in pediatrics Drug is appointed to children from 12 years in a herpesviridae infection, tick-borne encephalitis, Cytomegaloviral and papillomavirusny infections. Safety and efficiency of drug according to other indications at children and teenagers up to 18 years is not established. Pregnancy and the period of breastfeeding Use is possible in II and III trimester according to the indication persistent Cytomegaloviral infection in an aggravation stage as a part of complex therapy. In other cases the use is possible only if the expected advantage for mother exceeds potential risk for a fruit. In need of use of drug in the period of a lactation the breastfeeding for administration of drug should be stopped. Панавир® patients should not apply in case of presence of an allergy to compound components of drug: to glucose, mannose, rhamnose, pectine sugar, xylose. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms Data on a possibility of negative influence of drug on ability to control of vehicles and implementation of potentially dangerous types of activity requiring special attention and speed of psychomotor reactions no. Overdose Cases of overdose are not registered. Results of preclinical trials indicate hypotoxicity of drug. Forms of release and packing On 5 ml of solution in ampoules of neutral glass. On 2 or 5 ampoules pack into blister strip packaging from a film polyvinylchloride. On 1 blister strip packaging together with the instruction for medical use in the state and Russian languages and a knife ampoule or the scarificator to ampoule disk ceramic place in a pack from cardboard. When packing with notches the scarificator or a knife ampoule does not invest in ampoules. To Store storage conditions in the place protected from light, at a temperature from 2 °C to 25 °C. To store out of children’s reach! Not to apply a period of storage of 5 years after expiry date. Prescription status According to the prescription the Producer/packer of LLC Ellara Russia, 601122, the Vladimir Region, Petushinsky district. Cover, Franz Stolwerk St., 20, building 2. Owner of the registration certificate of LLC National Research Company Russia, 301404, Tula Region, Suvorov district, of Varushitsa, 104. The address of the organization in the territory of the Republic of Kazakhstan, the accepting claim (offer) on quality of medicines from consumers and responsible for post-registration observation of safety of medicine: Shamsun LLP, Republic of Kazakhstan, 050052, Almaty, Teplichnaya St., 12/16, apartment 1, ph. 8 (727) 239-19-59, e-mail: Amanzholov.Shamsun@gmail.com.